Novartis AG ADR (NVS)vsThird Harmonic Bio Inc. (THRD)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
THRD
Third Harmonic Bio Inc.
$5.38
0.00%
HEALTHCARE · Cap: $242.79M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
THRD
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for THRD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : THRD
The strongest argument for THRD centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : THRD
The primary concerns for THRD are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while THRD is a value play — different risk/reward profiles.
THRD carries more volatility with a beta of 2.13 — expect wider price swings.
THRD is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 32/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Third Harmonic Bio Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Third Harmonic Bio Inc. is an innovative biotechnology company dedicated to developing advanced therapies for severe immunological and inflammatory disorders. Utilizing its proprietary genetic engineering platform, the company is building a robust pipeline of drug candidates aimed at addressing significant unmet medical needs within the biopharmaceutical sector. Committed to scientific excellence and enhancing patient outcomes, Third Harmonic Bio is strategically positioned to reshape the treatment paradigm for patients facing serious health challenges, potentially delivering transformative solutions to the medical community.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?